Eli Lilly Quarterly Profit Drops on Cost of Dropping Drugs

Eli Lilly & Co. posted a 5 percent decline in fourth-quarter profit, held back by costs to stop developing the cholesterol drug evacetrapib and the insulin peglispro.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.